Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Olema Pharmaceuticals, Inc. (OLMA)
Company Research
Source: GlobeNewswire
On-track to report top-line data in the fall of 2026 from the pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with 2/3L ER+/HER2- metastatic breast cancerAdvanced enrollment in the OPERA-02 pivotal Phase 3 trial of palazestrant in combination with ribociclib in patients with frontline ER+/HER2- metastatic breast cancer Initiated the Phase 1b/2 study of palazestrant in combination with Pfizer’s novel CDK4 inhibitor, atirmociclib, in patients with ER+/HER2- metastatic breast cancerContinued enrollment in the Phase 1 clinical study of OP-3136 in breast cancer and other solid tumors, with initial clinical data expected in Q2 2026Generated $218.5 million in gross proceeds from a follow-on public offering, further strengthening the Company’s balance sheet; ended 2025 with $505.4 million in cash, cash equivalents, and marketable securitiesTransformation into a fully-integrated oncology company underway in preparation for the Company’s first potential commercial la
Show less
Read more
Impact Snapshot
Event Time:
OLMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OLMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OLMA alerts
High impacting Olema Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
OLMA
News
- Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual MeetingGlobeNewswire
- Olema Pharmaceuticals (OLMA) had its price target raised by Citigroup Inc. from $60.00 to $62.00. They now have a "buy" rating on the stock.MarketBeat
- Olema Pharmaceuticals (OLMA) had its price target lowered by Guggenheim from $40.00 to $38.00. They now have a "buy" rating on the stock.MarketBeat
- Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch [Yahoo! Finance]Yahoo! Finance
- Olema Pharmaceuticals GAAP EPS of -$0.50 beats by $0.01 [Seeking Alpha]Seeking Alpha
OLMA
Earnings
- 3/16/26 - Beat
OLMA
Sec Filings
- 3/16/26 - Form 144
- 3/16/26 - Form 144
- 3/16/26 - Form S-8
- OLMA's page on the SEC website